Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Bertrand Routy, John Lenehan, Wilson H. Miller, Rahima Jamal, Meriem Messaoudene, Brendan A. Daisley, Cecilia Hes, Kait F. Al, Laura Martínez-Gili, Michal Punčochář, Scott Ernst, Diane Logan, Karl Bélanger, Khashayar Esfahani, Corentin Richard, Marina Ninkov, Gianmarco Piccinno, Federica Armanini, Federica Pinto, Mithunah Krishnamoorthy, René Figueredo, Paméla Thébault, Panteleimon G. Takis, Jamie Magrill, LeeAnn Ramsay, Lisa Derosa, Julian R. Marchesi, Seema Nair Parvathy, Arielle Elkrief, Ian R. Watson, Réjean Lapointe, Nicola Segata, S. M. Mansour Haeryfar, Benjamin H. Mullish, Michael Silverman, Jeremy P. Burton, Saman Maleki Vareki
Topics & Concepts
PembrolizumabNivolumabMedicineTransplantationAdverse effectMicrobiomeClinical endpointMelanomaFecal bacteriotherapyInternal medicineImmune systemOncologyImmunologyImmunotherapyClinical trialClostridium difficileCancer researchBioinformaticsBiologyAntibioticsMicrobiologyGut microbiota and healthClostridium difficile and Clostridium perfringens researchCancer Immunotherapy and Biomarkers